Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 9/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11148838 | 0.86 | ALDH1A1 (0.35) | ESR1TP53HCAR3 | |
| SCHEMBL1770692 | 0.83 | ESR1 (0.43) | ESR1TP53HCAR3 | |
| SCHEMBL8812805 | 0.80 | HSD17B10 (0.43) | HCAR3 | |
| SCHEMBL5880844 | 0.77 | ALDH1A1 (0.46) | ESR1TP53HCAR3 | |
| SCHEMBL8975474 | 0.73 | GPR35 (0.36) | TP53 | |
| SCHEMBL8811691 | 0.73 | TSHR (0.47) | HCAR3 | |
| SCHEMBL7616291 | 0.73 | GPR35 (0.37) | — | |
| SCHEMBL5083037 | 0.72 | GPR35 (0.39) | — | |
| SCHEMBL1837510 | 0.72 | HTR1A (0.48) | HTR1AESR1TP53 | |
| SCHEMBL5373508 | 0.71 | GPR35 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352724-B1 | ARYL GUANIDINE F1F0-ATPASE INHIBITORS AND THEIR MEDICAL USE | UNIV MICHIGAN (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8497307-B2 | Aryl guanidine F1F0-ATPase inhibitors and related methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110251200-A1 | ARYL GUANIDINE F1F0-ATPASE INHIBITORS AND RELATED METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251200-A1 | ARYL GUANIDINE F1F0-ATPASE INHIBITORS AND RELATED METHODS | ATP5F1A, ATP5F1D, ATP5F1B | HTR1A 1218/4885ESR1 2049/4885TP53 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.